BR112023023501A2 - Método para diagnóstico e tratamento de indivíduos com polimorfismos de nucleotídeos únicos no cromossomo 2, locus 2:107.510.000107.540.000 - Google Patents

Método para diagnóstico e tratamento de indivíduos com polimorfismos de nucleotídeos únicos no cromossomo 2, locus 2:107.510.000107.540.000

Info

Publication number
BR112023023501A2
BR112023023501A2 BR112023023501A BR112023023501A BR112023023501A2 BR 112023023501 A2 BR112023023501 A2 BR 112023023501A2 BR 112023023501 A BR112023023501 A BR 112023023501A BR 112023023501 A BR112023023501 A BR 112023023501A BR 112023023501 A2 BR112023023501 A2 BR 112023023501A2
Authority
BR
Brazil
Prior art keywords
treatment
chromosome
locus
single nucleotide
nucleotide polymorphisms
Prior art date
Application number
BR112023023501A
Other languages
English (en)
Inventor
Moshe Laudon
Nava Zisapel
Original Assignee
Neurim Pharmaceuticals 1991 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals 1991 Ltd filed Critical Neurim Pharmaceuticals 1991 Ltd
Publication of BR112023023501A2 publication Critical patent/BR112023023501A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00659—Two-dimensional arrays
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00722—Nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

método para diagnóstico e tratamento de indivíduos com polimorfismos de nucleotídeos únicos no cromossomo 2, locus 2:107.510.000-107.540.000. métodos e produtos para identificar indivíduos que provavelmente responderão de maneira positiva (benefício) ou negativa (dano) a um tratamento farmacológico destinado ao tratamento ou prevenção de um distúrbio neuropsiquiátrico, neurodegeneração, ciclos de sono-vigília, incluindo, entre outros, a doença de alzheimer, esquizofrenia, autismo e distúrbios de atenção com base em polimorfismos de nucleotídeo único (snp) cromossomo 2, locus 2:107.510.000-107.540.000 (conforme descrito no genome reference consortium human genoma build 37 (grch37)).
BR112023023501A 2021-05-11 2022-05-10 Método para diagnóstico e tratamento de indivíduos com polimorfismos de nucleotídeos únicos no cromossomo 2, locus 2:107.510.000107.540.000 BR112023023501A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163187078P 2021-05-11 2021-05-11
PCT/IB2022/054347 WO2022238905A1 (en) 2021-05-11 2022-05-10 Method for diagnosing and treating subjects having single nucleotide polymorphisms in chromosome 2, 2:107,510,000-107,540,000 locus

Publications (1)

Publication Number Publication Date
BR112023023501A2 true BR112023023501A2 (pt) 2024-02-27

Family

ID=81846384

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023501A BR112023023501A2 (pt) 2021-05-11 2022-05-10 Método para diagnóstico e tratamento de indivíduos com polimorfismos de nucleotídeos únicos no cromossomo 2, locus 2:107.510.000107.540.000

Country Status (12)

Country Link
US (2) US11840731B2 (pt)
EP (1) EP4337793A1 (pt)
JP (1) JP2024519338A (pt)
KR (1) KR20240006657A (pt)
CN (1) CN117377777A (pt)
AU (1) AU2022272870A1 (pt)
BR (1) BR112023023501A2 (pt)
CA (1) CA3216790A1 (pt)
IL (1) IL307760A (pt)
MX (1) MX2023013420A (pt)
TW (1) TW202307217A (pt)
WO (1) WO2022238905A1 (pt)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151446A (en) 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680507B1 (fr) 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
JP2001017166A (ja) 1999-07-02 2001-01-23 Fuji Photo Film Co Ltd Ｄｎａチップ、ｄｎａチップの検定キットおよびｄｎａチップの検定法
US20020187490A1 (en) 2001-06-07 2002-12-12 Michigan State University Microbial identification chip based on DNA-DNA hybridization
US9119846B2 (en) * 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
US7635710B2 (en) 2006-02-15 2009-12-22 Neurim Pharmaceuticals (1991) Ltd. Pyrone-indole derivatives and process for their preparation
US9101613B2 (en) * 2006-02-15 2015-08-11 Neurim Pharmaceuticals (1991) Ltd. Methods for treating neurological disease
CN101821407B (zh) * 2007-07-10 2013-09-18 纽瑞姆制药（1991）有限公司 神经退行性疾病中的cd44剪接变体

Also Published As

Publication number Publication date
TW202307217A (zh) 2023-02-16
AU2022272870A9 (en) 2023-11-16
US20220364172A1 (en) 2022-11-17
US20220389508A1 (en) 2022-12-08
IL307760A (en) 2023-12-01
US11807907B2 (en) 2023-11-07
WO2022238905A1 (en) 2022-11-17
US11840731B2 (en) 2023-12-12
EP4337793A1 (en) 2024-03-20
CN117377777A (zh) 2024-01-09
AU2022272870A1 (en) 2023-11-02
CA3216790A1 (en) 2022-11-17
MX2023013420A (es) 2023-12-06
JP2024519338A (ja) 2024-05-10
KR20240006657A (ko) 2024-01-15

Similar Documents

Publication Publication Date Title
Imamura et al. Genetic and environmental factors of schizophrenia and autism spectrum disorder: insights from twin studies
Nakata et al. Association study of the brain-derived neurotrophic factor (BDNF) gene with bipolar disorder
Pagnamenta et al. Characterization of a family with rare deletions in CNTNAP5 and DOCK4 suggests novel risk loci for autism and dyslexia
Vandewalle et al. Dosage-dependent severity of the phenotype in patients with mental retardation due to a recurrent copy-number gain at Xq28 mediated by an unusual recombination
Neves-Pereira et al. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study
Shimada et al. MECP2 duplication syndrome in both genders
Huentelman et al. Association of SNPs in EGR3 and ARC with schizophrenia supports a biological pathway for schizophrenia risk
Rybakowski et al. Functional polymorphism of the matrix metalloproteinase-9 (MMP-9) gene in schizophrenia
Hyun et al. Rare variants in methionyl-and tyrosyl-tRNA synthetase genes in late-onset autosomal dominant Charcot-Marie-Tooth neuropathy.
Maron et al. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression
Lintas et al. Differential methylation at the RELN gene promoter in temporal cortex from autistic and typically developing post-puberal subjects
Alelú‐Paz et al. DNA methylation pattern of gene promoters of major neurotransmitter systems in older patients with schizophrenia with severe and mild cognitive impairment
Alfimova et al. Methylation of the reelin gene promoter in peripheral blood and its relationship with the cognitive function of schizophrenia patients
Fanizza et al. Genotype–phenotype relationship in a child with 2.3 Mb de novo interstitial 12p13. 33-p13. 32 deletion
Matsumoto et al. Serotonin transporter gene: a new polymorphism may affect response to antidepressant treatments in major depressive disorder
Mitra et al. Association of circulating BDNF levels with BDNF rs6265 polymorphism in schizophrenia
Schwaibold et al. Intragenic duplication of EHMT1 gene results in Kleefstra syndrome
Kunwar et al. Apert syndrome with S252W FGFR2 mutation and characterization using Phenomizer: an Indian case report
BR112023023501A2 (pt) Método para diagnóstico e tratamento de indivíduos com polimorfismos de nucleotídeos únicos no cromossomo 2, locus 2:107.510.000107.540.000
Wan et al. Early-onset schizophrenia: A special phenotype of the disease characterized by increased MTHFR polymorphisms and aggravating symptoms
Wu et al. Association of VEGF gene polymorphisms with sporadic Parkinson’s disease in Chinese Han population
PT1656458E (pt) Gene humano de susceptibilidade ao autismo e suas utilizações
Hayward et al. Fragile X syndrome in a male with methylated premutation alleles and no detectable methylated full mutation alleles
IL185868A0 (en) Human autism susceptibility gene encoding a transmembrane protein and uses thereof
Hernández-Rivera et al. NRAMP1 Polymorphisms like susceptibility marker in Mexican focus of cutaneous leishmaniasis